preclinical_heavy
Preclinical evidence exceeds central human evidence. Interpret translational relevance cautiously.
supportedtophigh inflation risk
Lipopolysaccharide biosynthesis
ulcerative colitis
Lipopolysaccharide biosynthesis has meaningful literature visibility in ulcerative colitis, but the current evidence mix suggests a substantial risk of overclaiming.
Lipopolysaccharide biosynthesis shows a moderate evidence base in ulcerative colitis, with multiple central papers and additional supporting literature.
lipopolysaccharide_biosynthesis
Credibility score
36
Human translation
1/5
Reproducibility
3/5
Novelty
3/5
Actionability
2/5
Credibility 36Human translation 1/5Reproducibility 3/5Novelty 3/5Actionability 2/5
Why this scores the way it does
- moderate central evidence base
- substantial preclinical support
Main caveats
- preclinical evidence outweighs human evidence
Internal review flags
1 flagsPrimary central evidence
6 papersSpecific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis.
2019Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer.
2022Anticancer research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Composition and diverse differences of intestinal microbiota in ulcerative colitis patients.
2022Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis.
2023Clinical and translational medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Biomarkers prediction and immune landscape in ulcerative colitis: Findings based on bioinformatics and machine learning.
2024Computers in biology and medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Reduced Sulfur Diet Reshapes the Microbiome and Metabolome in Mild-Moderate Ulcerative Colitis.
2025International journal of molecular sciences
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
38 papersThe microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition.
2014Proceedings of the National Academy of Sciences of the United States of America
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Lipopolysaccharides modulate intestinal epithelial permeability and inflammation in a species-specific manner.
2020Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Synbindin restrains proinflammatory macrophage activation against microbiota and mucosal inflammation during colitis.
2021Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-κB Axis.
2021Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Ganluyin ameliorates DSS-induced ulcerative colitis by inhibiting the enteric-origin LPS/TLR4/NF-κB pathway.
2022Journal of ethnopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis.
2022Theranostics
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Alleviative effects of natural plant polysaccharides against DSS-induced ulcerative colitis via inhibiting inflammation and modulating gut microbiota.
2023Food research international (Ottawa, Ont.)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Expression and significant roles of the lncRNA NEAT1/miR-493-5p/Rab27A axis in ulcerative colitis.
2023Immunity, inflammation and disease
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Disulfiram with Cu2+ alleviates dextran sulfate sodium-induced ulcerative colitis in mice.
2023Theranostics
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Network pharmacology mechanisms and experimental verification of licorice in the treatment of ulcerative colitis.
2024Journal of ethnopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Protective effects of Amauroderma rugosum on dextran sulfate sodium-induced ulcerative colitis through the regulation of macrophage polarization and suppression of oxidative stress.
2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Exploration of Berberine Against Ulcerative Colitis via TLR4/NF-κB/HIF-1α Pathway by Bioinformatics and Experimental Validation.
2024Drug design, development and therapy
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Epithelial Piezo1 deletion ameliorates intestinal barrier damage by regulating ferroptosis in ulcerative colitis.
2024Free radical biology & medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Oleanolic acid 28-O-β-D-glucopyranoside: A novel therapeutic agent against ulcerative colitis via anti-inflammatory, barrier-preservation, and gut microbiota-modulation.
2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Kui-Jie-Ling capsule inhibits ulcerative colitis by modulating inflammation and gut microbiota.
2024Journal of gastroenterology and hepatology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Berberine-loaded PLGA nanoparticles alleviate ulcerative colitis by targeting IL-6/IL-6R axis.
2024Journal of translational medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Galactooligosaccharides and Limosilactobacillus reuteri synergistically alleviate gut inflammation and barrier dysfunction by enriching Bacteroides acidifaciens for pentadecanoic acid biosynthesis.
2024Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Sishen Pill & Tongxieyaofang ameliorated ulcerative colitis through the activation of HIF-1α acetylation by gut microbiota-derived propionate and butyrate.
2025Phytomedicine : international journal of phytotherapy and phytopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Polyphenols-rich Portulaca oleracea L. (purslane) alleviates ulcerative colitis through restiring the intestinal barrier, gut microbiota and metabolites.
2025Food chemistry
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Polystyrene nanoplastics promote colitis-associated cancer by disrupting lipid metabolism and inducing DNA damage.
2025Environment international
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Oxyberberine alleviates lipopolysaccharide-induced intestinal barrier disruption and inflammation in human colonic Caco-2 cells in vitro.
2024Frontiers in pharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.
2025Molecular medicine (Cambridge, Mass.)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Amomum tsaoko flavonoids attenuate ulcerative colitis by inhibiting TLR4/NF-κB/NLRP3 signaling pathway and modulating gut microbiota in mice.
2025Frontiers in microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Kurarinone and Nor-kurarinone inhibit NLRP3 inflammasome activation and regulate macrophage polarization against ulcerative colitis.
2025International immunopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients.
2025Journal of Crohn's & colitis
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Plantamajoside alleviates DSS-induced ulcerative colitis by modulating gut microbiota, upregulating CBS, and inhibiting NF-κB.
2025Phytomedicine : international journal of phytotherapy and phytopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The RNA-binding E3 ligase MKRN2 selectively disrupts Il6 translation to restrain inflammation.
2025Nature immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
HIF-1α alleviates ferroptosis in ulcerative colitis by regulation of GPX4.
2025Cell death & disease
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Intestinal inflammation and microbiota modulation impact cochlear function: emerging insights in gut-ear axis.
2025Cell communication and signaling : CCS
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Magnoflorine alleviates colitis-induced anxiety-like behaviors by regulating gut microbiota and microglia-mediated neuroinflammation.
2025Microbiome
Disease-relevant preclinical or model-based paper useful as supporting evidence.
YTHDC1 Overexpression Inhibits Inflammation and Promotes Autophagy to Ameliorate Ulcerative Colitis Through the XBP1/AMPK/mTOR Pathway.
2025Journal of biochemical and molecular toxicology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Bifidobacterium longum subsp. infantis CCFM1426 enhances the anti-colitic effect of vitamin A via retinoic acid restoration and gut microbiota modulation in ulcerative colitis mice.
2025Frontiers in nutrition
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Lacticaseibacillus paracasei L21 and Its Postbiotics Ameliorate Ulcerative Colitis Through Gut Microbiota Modulation, Intestinal Barrier Restoration, and HIF1α/AhR-IL-22 Axis Activation: Combined In Vitro and In Vivo Evidence.
2025Nutrients
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Limonene alleviated ulcerative colitis via anti-inflammation, anti-oxidation and regulating intestinal microenvironment in vivo and in vitro.
2025Inflammopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
m6A modification and SUMOylation of PHGDH regulates ulcerative colitis through autophagy.
2025Cellular and molecular life sciences : CMLS
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Parasutterella excrementihominis exacerbates experimental colitis and colitis-associated colorectal cancer via pathogenic NETosis activation.
2026Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gypensapogenin I reduces inflammation and modulates gut microbiota in ulcerative colitis by targeting AKT1.
2026Journal of ethnopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Akebia saponin D attenuates ulcerative colitis via targeting EGFR and remodeling gut microbiota homeostasis.
2026Phytomedicine : international journal of phytotherapy and phytopharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
6 papersImmune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects.
2003Current pharmaceutical design
Relevant review or meta-analysis for the signal-disease area.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
2020Autophagy
Relevant review or meta-analysis for the signal-disease area.
Interaction between Lipopolysaccharide and Gut Microbiota in Inflammatory Bowel Diseases.
2021International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease.
2022Journal of advanced research
Relevant review or meta-analysis for the signal-disease area.
The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management.
2022Gut microbes
Relevant review or meta-analysis for the signal-disease area.
Paeoniflorin promotes intestinal stem cell-mediated epithelial regeneration and repair via PI3K-AKT-mTOR signalling in ulcerative colitis.
2023International immunopharmacology
Relevant review or meta-analysis for the signal-disease area.